Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving oxidoreductase
Reexamination Certificate
2005-02-15
2005-02-15
Gitomer, Ralph (Department: 1651)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving oxidoreductase
C546S160000
Reexamination Certificate
active
06855512
ABSTRACT:
A method of identifying a compound which is an inhibitor of the enzyme cytochrome P450RAI is performed by selecting a compound that has retinoid activity in an art recognized assay and includes a benzoic acid, benzoic acid ester, naphthoic acid ester or heteroaryl carboxylic acid or ester moiety, with a partial structure of —A(R2)—(CH2)n—COOR8where n is 0 and the remaining variables are as described in the specification and claims. Thereafter, a compound having the cytochrome P450RAI inhibitory activity is identified and selected where the compound has the —A(R2)—(CH2)2—COOR8partial structure wherein the variable n is 1 or 2.
REFERENCES:
patent: 4326055 (1982-04-01), Loeliger
patent: 4539154 (1985-09-01), Krebs
patent: 4723028 (1988-02-01), Shudo
patent: 4739098 (1988-04-01), Chandraratna
patent: 4740519 (1988-04-01), Shroot et al.
patent: 4810804 (1989-03-01), Chandraratna
patent: 4826969 (1989-05-01), Maignan et al.
patent: 4826984 (1989-05-01), Berlin et al.
patent: 4833240 (1989-05-01), Maignan et al.
patent: 4855320 (1989-08-01), Chatterjee et al.
patent: 4923884 (1990-05-01), Chandraratna
patent: 4980369 (1990-12-01), Chandraratna
patent: 4992468 (1991-02-01), Chandraratna
patent: 5006550 (1991-04-01), Chandraratna
patent: 5013744 (1991-05-01), Chandraratna
patent: 5015658 (1991-05-01), Chandraratna
patent: 5023341 (1991-06-01), Chandraratna
patent: 5037825 (1991-08-01), Klaus et al.
patent: 5045551 (1991-09-01), Chandraratna
patent: 5089509 (1992-02-01), Chandraratna
patent: 5130335 (1992-07-01), Chandraratna
patent: 5134159 (1992-07-01), Chandraratna
patent: 5149705 (1992-09-01), Chandraratna
patent: 5202471 (1993-04-01), Chandraratna
patent: 5264578 (1993-11-01), Chandraratna
patent: 5326898 (1994-07-01), Chandraratna
patent: 5346895 (1994-09-01), Chandraratna
patent: 5346915 (1994-09-01), Chandraratna
patent: 5348972 (1994-09-01), Chandraratna
patent: 5391753 (1995-02-01), Chandraratna
patent: 5399561 (1995-03-01), Chandraratna
patent: 5426118 (1995-06-01), Chandraratna et al.
patent: 5434173 (1995-07-01), Chandraratna
patent: 5455265 (1995-10-01), Chandraratna
patent: 5466861 (1995-11-01), Dawson et al.
patent: 5498795 (1996-03-01), Song et al.
patent: 5534641 (1996-07-01), Song et al.
patent: 5559248 (1996-09-01), Starrett, Jr. et al.
patent: 5563292 (1996-10-01), Sheh et al.
patent: 5602130 (1997-02-01), Chandraratna
patent: 5616597 (1997-04-01), Chandraratna
patent: 5616712 (1997-04-01), Teng et al.
patent: 5648503 (1997-07-01), Vuligonda et al.
patent: 5663347 (1997-09-01), Chandraratna
patent: 5663357 (1997-09-01), Teng et al.
patent: 5675024 (1997-10-01), Teng et al.
patent: 5688957 (1997-11-01), Teng et al.
patent: 5723666 (1998-03-01), Vuligonda et al.
patent: 5739338 (1998-04-01), Beard et al.
patent: 5773594 (1998-06-01), Johnson et al.
patent: 5856490 (1999-01-01), Teng et al.
patent: 5917048 (1999-06-01), Teng et al.
patent: 5952345 (1999-09-01), Klein et al.
patent: 5965606 (1999-10-01), Teng et al.
patent: 5998471 (1999-12-01), Johnson et al.
patent: 6025388 (2000-02-01), Nagpal et al.
patent: 6048873 (2000-04-01), Vasudevan et al.
patent: 6063606 (2000-05-01), Petkovich et al.
patent: 6252090 (2001-06-01), Vasudevan et al.
patent: 6291677 (2001-09-01), Vasudevan et al.
patent: 6303785 (2001-10-01), Johnson
patent: 6313107 (2001-11-01), Vasudevan et al.
patent: 6369225 (2002-04-01), Vasudevan et al.
patent: 6369261 (2002-04-01), Johnson et al.
patent: 6380256 (2002-04-01), Vasudevan et al.
patent: 6387951 (2002-05-01), Vasudevan et al.
patent: 6495552 (2002-12-01), Vasudevan et al.
patent: 6603019 (2003-08-01), Vasudevan et al.
patent: 3316932 (1983-11-01), None
patent: 3524199 (1986-01-01), None
patent: 3602473 (1987-07-01), None
patent: 3708060 (1987-09-01), None
patent: 3715955 (1987-11-01), None
patent: 0098591 (1984-01-01), None
patent: 0130795 (1985-01-01), None
patent: 0170105 (1986-02-01), None
patent: 0176034 (1986-04-01), None
patent: 0253302 (1988-01-01), None
patent: 0286364 (1988-10-01), None
patent: 0199636 (1989-02-01), None
patent: 0303915 (1989-02-01), None
patent: 0514269 (1992-11-01), None
patent: 0617020 (1994-09-01), None
patent: 0619116 (1994-10-01), None
patent: 0661259 (1995-05-01), None
patent: 2190378 (1987-11-01), None
patent: 6072866 (1994-03-01), None
patent: 8500806 (1985-02-01), None
patent: 8504652 (1985-10-01), None
patent: 9116051 (1991-10-01), None
patent: 9206948 (1992-04-01), None
patent: 9311755 (1993-06-01), None
patent: 9504036 (1995-02-01), None
patent: 9605165 (1996-02-01), None
patent: WO0218361 (2002-03-01), None
Kuijper, et al., “The effects of oral liarozole on epidermal proliferation and differentiation in severe plaque psoriasis are comparable with those of acitretin”,British Journal of Dermatology, (1998) 139: pp 380-389.
Kang, et al., “Liarozole Inhibits Human Epidermal Retinoid Acid 4-Hydroxylase Activity and Differentially Augments Human Skin Responses to Retinoic Acid and Retinol In Vivo”,The Journal of Investigative Dermatology, (Aug. 1996) vol. 107, No. 2: pp 183-187.
VanWauwe, et al., “Liarozole, an Inhibitor of Retinoic Acid Metabolism, Exerts Retinoid-Mimetic Effects in Vivo”,The Journal of Pharmacology and Experimental Therapeutics, (1992) vol. 261, No. 2: pp 773-779.
De Porre, et al., “Second Generation Retinoic Acid Metabolism Blocking Agent (Ramba) R116010: Dose Finding in Healthy Male Volunteers”, University of Leuven, Belgium, pp 30, no date given incomplete citation.
VanWauwe, et al., “Ketoconazole Inhibits the in Vitro and in Vivo Metabolism of All-Trans-Retinoic Acid”,The Journal of Pharmacology and Experimental Therapeutics, (1988) vol. 245, No. 2: pp 718-722.
White, et al., “cDNA Cloning of a Human Retinoic Acid-metabolizing Enzyme (hP450RAI) Identifies a Novel Family of Cytochromes P450 (CYP26)*”,The Journal of Biological Chemistry, (1997) vol. 272, No. 30, Issue of Jul. 25 pp 18538-18541.
Hanzlik, et al., “Cyclopropylamines as Suicide Substrates for Cytochromes P450RAI”,Journal of Medicinal Chemistry(1979), vol. 22, No. 7, pp 759-761.
Ortiz de Montellano, “Topics in Biology—The Inactivation of Cytochrome P450RAI”,Annual Reports in Medicinal Chemistry, (1984), Chapter 20, pp 201-210.
Hanzlik, et al., “Suicidal Inactivation of Cytochrome P450RAI by Cyclopropylamines Evidence for Cation-Radical Intermediates”,J. Am. Chem. Soc., (1982), vol. 104, No. 107, pp. 2048-2052.
Dawson, et al., “Chemistry and Biology of Synthetic Retinoids”, published byCRC Press, Inc., (1990), pp. 324-356.
Bligh et al., (1959) Canadian Journal of Biochemistry 37, pp. 911-917.
Feigner P. L. and Holm M. (1989) Focus, 112.
Heyman, et al., Cell 68, 397-406 (1992).
Allegretto, et al., J. Biol. Chem. 268, 26625-26633, no date given.
Mangelsdorf, et al., The Retinoids: Biology, Chemistry and Medicine, pp 319-349, Raven Press Ltd., New York, no date given.
Cheng, et al., Biochemistry Pharmacology vol. 22 pp 3099-3108, no date given.
Standeven et al., “Specific antagonist of retinoid toxicity in mice”,Toxicol. Appl. Pharmacol., 138: 169-175, (1996).
Thacher, et al., “Receptor specifically of retinoid-induced hyperplasia. Effect of RXR-selective agonist and correlation with topical irritation”,J. Pharm. Exp. Ther., 282:528-534 (1997).
Eyrolles et al.,J. Med. Chem., (1994), 37, 1508-1517.
Graupner et al.,Biochem. And Biophysical Research Communications, (1991), 1554-1561.
Kagechika, et al.,J. Med. Chem., (1988), 31, 2182-2192.
Bernard et al.Biochem. Biophys. Res. Commun., 1992 vol. 186, 977-983.
Chandraratna et al., J. Eur. J. Med. Chem., Suppl. to vol. 30, 1995, 506s-517s.
Winum et al., Il Farmaco, 1997, vol. 52, 1, pp. 39-42.
White, Jay A. et al., Proceedings of the National Academy of Sciences of USA, National Academy of Science, vol. 97, No. 12, Jun. 6, 2000.
Njar, V.C.O., et al., Biorganic & Medicinal Chemistry Letters, Oxford, G.B.; vol. 10, No. 17, Sep. 2000, pp 1905-1908, XP004214134.
White, Jay
Chandraratna Roshantha A.
Huang Dehua
Johnson Alan T.
Vasudevan Jayasree
Wang Liming
Allergan Inc.
Gitomer Ralph
Szekeres Gabor L.
LandOfFree
Methods for identifying inhibitors of cytochrome P450RAI does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for identifying inhibitors of cytochrome P450RAI, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for identifying inhibitors of cytochrome P450RAI will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3459441